AEZS vs. KERX
Centi, Du hast Dich ja, wenn ich mich richtig erinnere, unheimlich tief mit der ganzen Zopt-Materie beschäftigt. Glaubst Du, dass die Studie damals irgendwie bewusst falsch angelegt wurde, und wenn ja, welchen Vorteil könnte das für das Managament gehabt haben, wenn das doch Zeug doch eigentlich wirkt und ein großes Potential gehabt hätte?
nice weekend, trotzdem...
Überzeugen kann das Managment tatsächlich nicht. Weder im Bezug auf Informationen, noch aus fachlicher Sicht.
Eigentlich bin ich mir zu 100 Prozent sicher, das demnächst der RS kommt. Aber jetzt verkaufen macht keinen Sinn. Also weiter abwarten und dann eben entscheiden!!
Ich sehe gerade, der Kursverlauf ist ja mal wieder in der richtigen Richtung... ziemlich manipuliert das Ganze. Nur kann man da nur als kleiner Mann zusehen, oder eben dem ein Ende bereiten!!
Ich wünsche Allen Investierten viel Erfolg mit Ihren Entscheidungen und hoffe, das die Ganoven zumindest mal etwas für den Anleger tun.....
Die Studie hatte eigentlich keine Mängel. Dass sie bewust die Kiste gegen die Wand gefahren haben, sehe ich auch nicht.
Eventuell haben sie zu hoch gepokert. Dadurch wurde die Resistenzumgehung nicht richtig ausgespielt.
Größter Fehler war doch eigentlich, dass es keine von der FDA zugelassene Validierung zur LHRH Patientenbestimmung gibt. Somit sind Patienten in die Studie aufgenommen worden die praktisch ein Plazebo verabreicht bekommen haben, was m.E. auch zu den Herzproblemen geführt haben könnte.
Q.
Is it true that patients whose tumor did not express the LHRH receptor were enrolled in the study? Why?
A.
It is true that patients whose tumor may not express the LHRH receptor were enrolled in the study. This was done because the FDA required us to admit all patients with the disease specified in the protocol. There were two reasons for the FDA’s position. First, at the start of the trial there was no validated companion diagnostic tool available to determine whether a tumor expresses the LHRH receptor (and we were not able to develop such a tool during the trial). Second, the consensus among oncologists is that most tumors associated with the disease specified in the protocol express LHRH receptors.
The LHRH receptor is aberrantly present on the cell surface of approximately 80% of endometrial and ovarian cancers, 86% of prostate cancers and about 50% of breast cancers
AEZS-108 267 mg/m2 (equimolar to 76.8 mg/m2 of free doxorubicin)
Ich bin kein Mediziner. Ich frage mich wo das Zopt-Dox im Körper abgebaut wird wenn es nicht in die angedachten Zellen gelangt.
M.E. wird das Dox nach und nach im Körper freigegeben, wodurch eine erhöhte Anreicherung entsteht. In etwa wie freies Dox.
Zopt ist nicht schlecht, muss nur richtig angewendet werden!
@Fish: Ich wusste gar nicht mehr, dass das "Gerücht" hier in Ariva durch Dich diskutiert wurde. Ich glaube aber, im Yahoo Forum hatte ich das auch irgendwo gelesen. Und überhaupt keinen Vorwurf - jeder kann sich natürlich seine Gedanken machen und nach Erklärungen suchen - es hätte ja auch wesentlich mehr Sinn gemacht als auf die dann gewählte Weise seinen Aktionären eine solche KE anzutun.
Da werden einige unter den 5% geblieben sein. Die schon über den 5% lagen, brauchen dann auch erst über 10% wieder ein 13G. Oder halt unter der 5% Marke, wobei die 10 Tage Berichtszeit nicht greift.
Beim 13D sind auch wieder ander Zeiten einzuhalten.
Schwere Kost mit den Berichtszeiten. Da Blicke ich nicht ganz durch.
The percentage of shares owned prior to and after the offering is based on 23,546,971 of our Common Shares outstanding as of May 29, 2020.
Common Shares Beneficially Owned Prior to the Offering | Common Shares Beneficially Owned Prior to the Offering | | Number of Common Shares Registered Hereby |
| ||||
Number | for Sale | Number | ||||||
Empery Asset Master, LTD(1) | 497,733 | 362,585 | 135,148 | * | ||||
Empery Tax Efficient II, LP(2) | 1,094,950 | 894,098 | 200,852 | * | ||||
Empery Tax Efficient, LP(3) | 68,317 | 68,317 | - | - | ||||
Armistice Capital Master Fund Ltd.(4) | 3,739,130 | 3,739,130 | - | - | ||||
Lincoln Park Capital Fund, LLC(5) | 579,710 | 579,710 | - | - | ||||
Intracoastal Capital, LLC(6) | 429,856 | 289,856 | 140,000 | * | ||||
Noam Rubinstein(7)(11) | 76,696 | 76,696 | - | - | ||||
Charles Worthman(8)(11) | 2,435 | 2,435 | - | - | ||||
Michael Vasinkevich(9)(11) | 156,130 | 156,130 | - | - | ||||
Craig Schwabe(10)(11) | 8,217 | 8,217 | - | - | ||||
Total Common Shares Registered Hereby: | 6,177,174 |
* | Less than 1%. |
** | Subject to a 4.99% blocker. See notes below. |
(1) Consists of 497,733 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. Empery Asset Management LP, the authorized agent of Empery Asset Master Ltd (“EAM”), has discretionary authority to vote and dispose of the shares held by EAM and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares. The registered address of EAM is c/o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, NY 10020.
(2) Consists of 1,094,950 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. Empery Asset Management LP, the authorized agent of Empery Tax Efficient II, LP (“ETE II”), has discretionary authority to vote and dispose of the shares held by ETE II and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by ETE II. ETE II, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares. The registered address of ETE II is c/o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, NY 10020.
(3) Consists of 68,317 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. Empery Asset Management LP, the authorized agent of Empery Tax Efficient, LP (“ETE”), has discretionary authority to vote and dispose of the shares held by ETE and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by ETE. ETE, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares. The registered address of ETE is c/o Empery Asset Management, LP, One Rockefeller Plaza, Suite 1205, New York City, NY 10020.
(4) Consists of 3,739,130 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. The business address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, L.L.C., 510 Madison Avenue, 7th Floor, New York, New York 10022. Steven Boyd, the managing member of Armistice Capital, LLC, the investment manager of Armistice Capital Master Fund Ltd., has the power to vote and dispose of the shares held by Armistice Capital Master Fund Ltd. and may be deemed to be the beneficial owner of these shares.
(5) Consists of 579,710 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. The registered address of Lincoln Park Capital Fund, LLC (“Lincoln Park”) is 440 N. Wells St., Suite 410, Chicago, IL 60654. Josh Scheinfeld and Jonathan Cope, the principals of Lincoln Park, are deemed to be beneficial owners of all of the Common Shares owned by Lincoln Park. Messrs. Cope and Scheinfeld have shared voting and dispositive power over the Common Shares being offered under this prospectus.
(6) Consists of 429,856 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein. The registered address of Intracoastal Capital, LLC is 245 Palm Trail, Delray Beach, FL 33483. Mitchell P. Kopin (“Mr. Kopin”) and Daniel B. Asher (“Mr. Asher”), each of whom are managers of Intracoastal Capital LLC (“Intracoastal”), have shared voting control and investment discretion over the securities reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) of the securities reported herein that are held by Intracoastal.
(7) Consists of 76,696 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein.
(8) Consists of 2,435 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein.
(9) Consists of 156,130 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein.
(10) Consists of 8,217 Common Shares underlying warrants, without giving effect to limitations on beneficial ownership set forth therein.
(11) Each of Noam Rubinstein, Charles Worthman, Michael Vasinkevich and Craig Schwabe have a registered address of 430 Park Ave, 3rd Floor, New York, NY 10022.
This Offering
We are registering for resale by the selling shareholders named herein the 6,177,174 Common Shares as described below.